Oncopeptides AB (ONCO) AI Stock Analysis

• Market Cap: kr394.22M
• Dividend Yield: N/A
• Average Volume (3M): 847.68K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.25
• Revenue Growth: -10.14%
• EPS Growth: 20.91%
• Country: SE
• Employees: 80
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -0.39
• Shares Outstanding: 211,263,900
• 10 Day Avg. Volume: 270,994
• 30 Day Avg. Volume: 847,681
• PEG Ratio: -0.06
• Price to Book (P/B): 7.19
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.48
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Oncopeptides AB's stock score is primarily affected by its poor financial performance, with ongoing losses and cash flow issues. The company's technical indicators suggest potential stabilization but remain weak overall. Valuation further emphasizes caution due to the negative P/E ratio. The absence of earnings call data and corporate events means these factors do not influence the score.

Oncopeptides AB Business Overview & Revenue Model

Company Description

Oncopeptides AB is a Sweden-based pharmaceutical company that focuses on the development of therapies for difficult-to-treat hematological diseases. The company's core product is melflufen (INN melphalan flufenamide), a peptide-drug conjugate intended for the treatment of multiple myeloma, which is a type of blood cancer. Oncopeptides leverages its proprietary Peptide-Drug Conjugate technology to deliver targeted treatments that improve the lives of patients with rare and hard-to-treat disorders.

How the Company Makes Money

Oncopeptides AB primarily generates revenue through the commercialization of its pharmaceutical products, particularly melflufen. As a biotechnology company, its revenue model relies heavily on the successful development, approval, and marketing of its drug candidates. The company engages in partnerships and collaborations with other pharmaceutical entities to enhance its research and development capabilities, expand its market reach, and secure funding. Additionally, Oncopeptides may earn revenue through licensing agreements and milestone payments from these collaborations. The company's financial performance is significantly influenced by regulatory approvals, clinical trial outcomes, and the competitive landscape within the hematology and oncology sectors.

Oncopeptides AB Financial Statement Overview

Summary

Overall, Oncopeptides AB is facing financial challenges characterized by persistent losses, high leverage, and cash flow shortfalls. The company needs to improve operational efficiency and profitability to enhance financial stability. Strengths include a strong cash position and the ability to secure financing to sustain operations.

Income Statement

Oncopeptides AB has shown inconsistent revenue trends with significant fluctuations over the years. The company has consistently reported negative net income, indicating ongoing losses. Additionally, the high negative EBIT margin reflects operational inefficiencies or high operating costs relative to revenue.

Balance Sheet

The company's balance sheet shows a high level of liabilities compared to its equity, indicating a high debt-to-equity ratio. However, the company maintains a relatively strong cash position, which could help manage short-term liabilities. The equity ratio has deteriorated over time, suggesting decreasing asset financing through equity.

Cash Flow

Oncopeptides AB has consistently reported negative operating and free cash flows, highlighting cash burn issues. Despite this, the company has managed to secure financing to support operations. The free cash flow to net income ratio is negative, emphasizing the challenge in generating cash from its core operations.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
31.65M	35.22M	8.36M	118.30M	0.00
	Gross Profit
28.98M	36.30M	8.35M	65.17M	-14.40M
	EBIT
-283.50M	-253.45M	-349.35M	-1.42B	-1.59B
	EBITDA
-283.50M	-231.62M	-319.62M	-1.40B	-1.58B
	Net Income Common Stockholders
-284.61M	-249.11M	-337.95M	-1.43B	-1.59B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
178.54M	173.44M	344.51M	362.19M	840.25M
	Total Assets
244.19M	238.38M	385.32M	439.38M	946.76M
	Total Debt
121.89M	126.16M	9.54M	14.19M	19.36M
	Net Debt
-56.64M	-47.25M	-334.97M	-347.99M	-820.90M
	Total Liabilities
189.91M	181.60M	91.03M	228.51M	369.86M
	Stockholders Equity
54.28M	56.78M	294.29M	210.87M	576.90M
Cash Flow		Free Cash Flow
-260.57M	-279.61M	-423.02M	-1.52B	-1.31B
	Operating Cash Flow
-260.57M	-279.49M	-420.51M	-1.52B	-1.30B
	Investing Cash Flow
496.00K	-116.00K	-2.51M	-339.00K	-20.13M
	Financing Cash Flow
263.81M	106.89M	392.40M	1.03B	1.32B

Oncopeptides AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.96
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ONCO, the sentiment is Positive. The current price of 1.96 is above the 20-day moving average (MA) of 1.93, above the 50-day MA of 1.72, and above the 200-day MA of 1.81, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 52.51 is Neutral, neither overbought nor oversold. The STOCH value of 26.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ONCO.

Oncopeptides AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.22B	3.55	-44.39%	2.82%	15.40%	-0.09%
XBRANE	48 Neutral	kr447.09M	―	-47.73%	―	45.52%	93.35%
ISOFOL	36 Underperform	kr262.62M	―	-42.88%	―	-100.00%	-17.35%
ONCO	33 Underperform	kr394.22M	―		―	-10.14%	20.91%
GUARD	32 Underperform	kr276.30M	―	-205.65%	―	―	24.25%
IMMU	32 Underperform	kr262.88M	―	-18.79%	―	―	21.85%
CANTA	31 Underperform	€412.70M	―	-111.62%	―	―	46.67%

Oncopeptides AB Corporate Events

Oncopeptides AB to Release Q1 2025 Financial Report

Oncopeptides AB announced the upcoming release of its Q1 2025 financial report, scheduled for May 15, 2025. The company will host a webcast and Q&A session for investors, analysts, and media, led by CEO Sofia Heigis and CFO Henrik Bergentoft. This event provides stakeholders an opportunity to gain insights into the company’s financial performance and strategic direction.